(Q37948705)

25 August 2017

Therapeutic drug monitoring of biologics for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

25 August 2017

0 references

inflammation

0 references

author

William Jeffery Sandborn

series ordinal

3

object named as

William J Sandborn

1 reference

25 August 2017

2

Brian G Feagan

1 reference

25 August 2017

4

Gert Van Assche

1 reference

PubMed ID

22021134

25 August 2017

Jean-Frédéric Colombel

series ordinal

1

object named as

Jean-Frédéric Colombel

1 reference

25 August 2017

Anne M Robinson

5

1 reference

25 August 2017

21 October 2011

1 reference

Inflammatory Bowel Diseases

25 August 2017

1 reference

25 August 2017

18

1 reference

25 August 2017

2

1 reference

25 August 2017

349-358

1 reference

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

25 August 2017

1 reference

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

21 January 2018

1 reference

Fc receptors and their interactions with immunoglobulins

21 January 2018

1 reference

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level

21 January 2018

1 reference

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

21 January 2018

1 reference

C-reactive protein as a marker for inflammatory bowel disease

21 January 2018

1 reference

Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

21 January 2018

1 reference

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

21 January 2018

1 reference

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

PEGylated antibodies and antibody fragments for improved therapy: a review

21 January 2018

1 reference

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

21 January 2018

1 reference

Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease

21 January 2018

1 reference

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Therapeutic drug monitoring

21 January 2018

1 reference

ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements

21 January 2018

1 reference

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Tailoring the length of antiviral treatment for hepatitis C.

21 January 2018

1 reference

Optimizing use of aminoglycosides in the critically ill.

21 January 2018

1 reference

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.21831

1 reference

25 August 2017

1 reference

PubMed ID

22021134